AbbVie Inc. v. Medimmune Limited, No. 17-1689 (Fed. Cir. Feb. 5, 2018)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

AbbVie, Inc. , and AbbVie Biotechnology Ltd. (“AbbVie”) filed suit in the Eastern District of Virginia against MedImmune Limited (“MedImmune”), seeking a declaratory judgment that U.S. Patent No. 6,248,516 (“the ’516 patent”) is invalid . The district court determined that it lacked jurisdiction under the Declaratory Judg- ment Act, 28 U.S.C. §§ 2201–02, and alternatively that it would not exercise jurisdiction if it existed, and it granted MedImmune’s motion to dismiss. We affirm.